Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357329 | 1.00 | CA12 (0.41) | CA12CA1MMP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5766910 | 0.85 | CA1 (0.49) | CA12CA1MMP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1259895 | 0.81 | CA1 (0.41) | CA12CA1MMP2ALDH1A1KIF11 | |
| SCHEMBL5424944 | 0.79 | CCNT1 (0.50) | CA12CA1MMP2SMN1; SMN2KIF11 | |
| SCHEMBL29245415 | 0.79 | ESR1 (0.44) | CA12CA1MMP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5359412 | 0.79 | CCNT1 (0.50) | CA12CA1MMP2SMN1; SMN2KIF11 | |
| SCHEMBL1734546 | 0.74 | CA12 (0.46) | CA12CA1MMP2ALDH1A1L3MBTL1 | |
| SCHEMBL14509044 | 0.74 | CA12 (0.46) | CA12CA1MMP2ALDH1A1KIF11 | |
| SCHEMBL1734544 | 0.74 | CA12 (0.46) | CA12CA1MMP2ALDH1A1L3MBTL1 | |
| SCHEMBL1937094 | 0.73 | KIF11 (0.45) | CA12CA1MMP2KIF11HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118998-A | Preparation method of CETP inhibitor Obicetrapib (AMG-899) | 上海相辉医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | ELI LILLY AND COMPANY (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | ELI LILLY AND COMPANY (US) | 2008-10-30 | — | — | US | disclosed |
| CN-100357265-C | Compounds useful as intermediates of 4-aminoquinoline deravative | PFIZER PROD INC (US) | 2007-12-26 | — | — | CN | disclosed |
| CN-1972927-A | Compounds and methods for treating dyslipidemia | LILLY CO ELI (US) | 2007-05-30 | — | — | CN | disclosed |
| US-7223859-B2 | Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1761521-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| US-6706881-B2 | 4-(METHOXYCARBONYL-AMINO)-2-ETHYL-6-TRIFLUOROMETHYL-3,4-DIHYDRO -2H-QUINOLINE-1-CARBOXYLIC ACID ETHYL ESTER IS REACTED WITH 3,5-BIS(TRIFLUOROMETHYL)BENZYL HALIDE IN BASE; ALKYLATION | PFIZER, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6689897-B2 | CHOLESTERYL ESTER TRANSFER PROTEIN | PFIZER INC. | 2004-02-10 | — | — | US | disclosed |
| EP-1383734-A2 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002088069-A9 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PROD INC (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030216576-A1 | Methods for preparing CETP inhibitors | PFIZER INC. | 2003-11-20 | — | — | US | disclosed |
| US-6600045-B2 | This invention relates to methods for preparing certain cholesteryl ester transfer protein (CETP) inhibitors and intermediates useful in the preparation of said CETP inhibitors. | PFIZER INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030073843-A1 | Methods for preparing CETP inhibitors | DAMON DAVID B (US) | 2003-04-17 | — | — | US | disclosed |
| US-20020177716-A1 | Intermediates of CETP inhibitors | DAMON DAVID B (US) | 2002-11-28 | — | — | US | disclosed |
| WO-2002088069-A2 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088085-A2 | METHODS AND INTERMEDIATES FOR PREPARING 4-AMINOQUINOLINE CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216576-A1 | Methods for preparing CETP inhibitors | CETP, LCAT, MTTP | CA12 4274/4885CA1 4371/4885MMP2 2032/4885 |
| US-20030073843-A1 | Methods for preparing CETP inhibitors | CETP, LCAT, MTTP | CA12 4274/4885CA1 4371/4885MMP2 2032/4885 |
| US-20020177716-A1 | Intermediates of CETP inhibitors | CETP, LCAT, MTTP | CA12 4085/4885CA1 4556/4885MMP2 2452/4885 |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, PCSK9, LIPC | CA12 4614/4885CA1 4535/4885MMP2 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.